HC Wainwright Has Negative Outlook of MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 15th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.16 per share for the year, down from their prior forecast of $0.19. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $0.58 EPS.

Several other analysts have also recently commented on MIST. TD Securities cut Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 1st. Cowen lowered Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Finally, TD Cowen lowered Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.00.

Milestone Pharmaceuticals Stock Down 1.2%

Shares of Milestone Pharmaceuticals stock opened at $1.65 on Wednesday. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 4.06. The business’s 50 day simple moving average is $1.67 and its 200-day simple moving average is $1.68. The stock has a market capitalization of $88.21 million, a price-to-earnings ratio of -2.12 and a beta of 0.96. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12).

Institutional Trading of Milestone Pharmaceuticals

A number of large investors have recently made changes to their positions in MIST. Jones Financial Companies Lllp lifted its stake in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. Bay Rivers Group bought a new stake in shares of Milestone Pharmaceuticals during the second quarter worth $28,000. XTX Topco Ltd grew its stake in shares of Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company’s stock worth $42,000 after buying an additional 17,950 shares during the last quarter. National Bank of Canada FI grew its stake in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth $73,000. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.